Kaur Ekjot, Sahu Aditi, Hole Arti R, Rajendra Jacinth, Chaubal Rohan, Gardi Nilesh, Dutt Amit, Moiyadi Aliasgar, Krishna C Murali, Dutt Shilpee
Shilpee Dutt Laboratory, Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Kharghar, Navi Mumbai 410210, India.
Chilakapati Laboratory, Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Kharghar, Navi Mumbai 410210, India.
Sci Rep. 2016 May 25;6:26538. doi: 10.1038/srep26538.
An inability to discern resistant cells from bulk tumour cell population contributes to poor prognosis in Glioblastoma. Here, we compared parent and recurrent cells generated from patient derived primary cultures and cell lines to identify their unique molecular hallmarks. Although morphologically similar, parent and recurrent cells from different samples showed variable biological properties like proliferation and radiation resistance. However, total RNA-sequencing revealed transcriptional landscape unique to parent and recurrent populations. These data suggest that global molecular differences but not individual biological phenotype could differentiate parent and recurrent cells. We demonstrate that Raman Spectroscopy a label-free, non-invasive technique, yields global information about biochemical milieu of recurrent and parent cells thus, classifying them into distinct clusters based on Principal-Component-Analysis and Principal-Component-Linear-Discriminant-Analysis. Additionally, higher lipid related spectral peaks were observed in recurrent population. Importantly, Raman spectroscopic analysis could further classify an independent set of naïve primary glioblastoma tumour tissues into non-responder and responder groups. Interestingly, spectral features from the non-responder patient samples show a considerable overlap with the in-vitro generated recurrent cells suggesting their similar biological behaviour. This feasibility study necessitates analysis of a larger cohort of naïve primary glioblastoma samples to fully envisage clinical utility of Raman spectroscopy in predicting therapeutic response.
无法从大量肿瘤细胞群体中识别出耐药细胞是胶质母细胞瘤预后不良的一个原因。在此,我们比较了源自患者原代培养物和细胞系的亲本细胞和复发细胞,以确定它们独特的分子特征。尽管形态相似,但来自不同样本的亲本细胞和复发细胞表现出不同的生物学特性,如增殖和抗辐射能力。然而,全RNA测序揭示了亲本群体和复发群体独特的转录图谱。这些数据表明,整体分子差异而非个体生物学表型可以区分亲本细胞和复发细胞。我们证明,拉曼光谱法作为一种无标记、非侵入性技术,能够提供有关复发细胞和亲本细胞生化环境的整体信息,从而基于主成分分析和主成分线性判别分析将它们分为不同的簇。此外,在复发群体中观察到更高的脂质相关光谱峰。重要的是,拉曼光谱分析可以进一步将一组独立的原发性胶质母细胞瘤肿瘤组织样本分为无反应组和反应组。有趣的是,无反应患者样本的光谱特征与体外产生的复发细胞有相当大的重叠,表明它们具有相似的生物学行为。这项可行性研究需要分析更大规模的原发性胶质母细胞瘤样本队列,以全面设想拉曼光谱在预测治疗反应方面的临床应用价值。